Abstract Number: L07 • ACR Convergence 2022
Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…Abstract Number: 0082 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) are considered at risk for serious COVID infections due to their…Abstract Number: 0221 • ACR Convergence 2022
Identifying and Addressing Gaps in Systemic Lupus Erythematosus Care via Multimodal Continuing Medical Education
Background/Purpose: Given the recent advances in the management of patients systemic lupus erythematosus (SLE), rheumatology and primary care providers are challenged to administer the latest…Abstract Number: 0334 • ACR Convergence 2022
Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records
Background/Purpose: Real-world data could provide valuable information in the study of lupus nephritis (LN), if these cases could be reliably identified. A lack of ability…Abstract Number: 0351 • ACR Convergence 2022
The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study
Background/Purpose: Low disease activity (LDA) and remission in patients with systemic lupus erythematosus (SLE) can reduce organ damage accrual and improve prognosis. We investigated the…Abstract Number: 0517 • ACR Convergence 2022
Cortical Surface Area Correlates with Cognitive Efficiency and Disease Measures in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Cognitive difficulties are common in children with childhood-onset SLE (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase understanding of…Abstract Number: 0638 • ACR Convergence 2022
Identification of New Candidate Drugs for SLE Using a Drug Repurposing Transcriptomic Approach on Blood, Skin and Kidney Samples from 3439 Patients
Background/Purpose: Despite improvements in the understanding of the pathogenesis of Systemic Lupus Erythematosus (SLE), very few new treatments have proven their effectiveness. Drug development is…Abstract Number: 0658 • ACR Convergence 2022
Integrative Analysis of Cell-Specific Human Endogenous Retrovirus Expression and Host Gene Expression Identifies Associations with Clinical SLE Phenotypes
Background/Purpose: Human endogenous retroviruses (HERVs) and long interspersed nuclear elements (LINEs) make up 5-8% and 21% of the human genome, respectively. Their expression may contribute…Abstract Number: 0746 • ACR Convergence 2022
Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial
Background/Purpose: During the pandemic, vulnerable patients such as those with lupus nephritis (LN) faced the difficult choice between COVID-19 infection risk during a clinic visit…Abstract Number: 0962 • ACR Convergence 2022
Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm
Background/Purpose: Disparities in pregnancy outcomes among women with SLE remain understudied, with few available racially-diverse datasets. We previously validated algorithms to identify pregnancies in women…Abstract Number: 0983 • ACR Convergence 2022
Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Initially used as an antimalarial, hydroxychloroquine (HCQ) is standard of care treatment for systemic lupus erythematosus (SLE) and is used as monotherapy or adjunct…Abstract Number: 1000 • ACR Convergence 2022
Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study
Background/Purpose: Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines (eg, Type 1 IFNs, IL-23, and IL-12) involved in lupus pathogenesis. Deucravacitinib (DEUC) has a…Abstract Number: 1192 • ACR Convergence 2022
Celiac Disease in Patients with Systemic Lupus Erythematosus: An Analysis of Nationwide Inpatient Sample
Background/Purpose: Celiac disease is an autoimmune disease characterized by the immunologic reaction to gluten by lymphocytes. Although recent studies suggest an association between celiac disease…Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…
- 1
- 2
- 3
- …
- 88
- Next Page »